Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review

Background: Based on the VIALE-A and VIALE-C studies, the Food and Drug Administration approved venetoclax in 2020 in combination with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia ineligible for intensive chemotherapy. After the publication of these st...

Full description

Saved in:
Bibliographic Details
Main Authors: Lauro Fabián Amador-Medina, Erick Crespo-Solís, Francisco Javier Turrubiates-Hernández, Karla Edith Santibañez-Bedolla
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Hematology, Transfusion and Cell Therapy
Subjects:
Acute myeloid leukemia
Venetoclax
Azacitidine
Low-dose cytarabine
Ineligible for intensive chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137924003304
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items